


Annual Report 2021

Impact of COVID19 in England in 2020

Impact on **Diagnosis**


Number of patients newly diagnosed with prostate cancer in 2020 (compared to same period in 2019)



* There was a 54% reduction in the number of men diagnosed between April - June 2020 compared with same period in 2019


Impact on radical treatment received

Number of patients undergoing radical prostatectomy in 2020 (compared to same period in 2019)



* There was a 48% reduction in the number of men undergoing prostatectomy between April - June 2020 compared with same period in 2019

Number of patients undergoing radical radiotherapy in 2020 (compared to same period in 2019)



Impact on systemic therapy

Rapid and marked **fall of Docetaxel use** from April 2020 in metastatic hormonesensitive prostate cancer. Conversely, rapid and marked **increased use of Enzalutamide**

